Vivesto’s pipeline of development programs includes Cantrixil, in clinical development for difficult to treat cancer, and Docetaxel micellar, in development for advanced prostate cancer.
Vivesto’s pipeline of development programs includes Cantrixil, in clinical development for difficult to treat cancer, and Docetaxel micellar, in development for advanced prostate cancer.